Expert Review of Hematology

Article	Citations
D-dimer level in COVID-19 infection: a systematic review	224
Genetic risk factors for venous thromboembolism	45
Evidence-based indications of platelet-rich plasma therapy	41
Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures	37
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd	32
A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’	29
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia	27
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	23
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians	23
Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits	22
The biology and management of dyskeratosis congenita and related disorders of telomeres	21
Complement activation and coagulopathy - an ominous duo in COVID19	20
Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape	20
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	20
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma	19
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	18
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses	18
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis	18
Safety of FLT3 inhibitors in patients with acute myeloid leukemia	17
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	17
Avapritinib for Systemic Mastocytosis	17
The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review	17
Prophylaxis for hemophilia A without inhibitors: treatment options and considerations	16
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms	15
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	15

Managing patients with hematological malignancies during COVID-19 pandemic	15
Hemostatic defects in massive transfusion: an update and treatment recommendations	15
Clinical spectrum, risk factors, management and outcome of patients with retroperitoneal hematoma: a retrospective analysis of 3-year experience	15
Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors	15
Hematological manifestations and complications of Gaucher disease	14
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	13
Voxelotor for the treatment of sickle cell disease	13
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology	13
Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment	12
Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis	12
MRI detection of brain abnormality in sickle cell disease	12
Immune thrombocytopenia	12
Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients	12
Apoptosis targeted therapies in acute myeloid leukemia: an update	12
Screening tools for hereditary hemolytic anemia: new concepts and strategies	11
Evolution of the role of haploidentical stem cell transplantation: past, present, and future	11
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	11
Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma	11
Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?	11
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development	11
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review	11
Pharmacological management of rare coagulation factor deficiencies besides hemophilia	10
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	10
Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma	10
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	10
Biomarkers for acute and chronic graft versus host disease: state of the art	10
Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from	10
Enhancing CAR T cell efficacy: the next step toward a clinical revolution?	10
What is the future of patient-reported outcomes in sickle-cell disease?	10
Renal disease associated with chronic myeloproliferative neoplasms	10
COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals	10
Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study	9
Sickle cell disease as a vascular disorder	9
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies	9
Targeting CD123 in BPDCN: an emerging field	8
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	8
Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia	8
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	8
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia	8
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?	8
Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies	8
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura	8
Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence	8
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond	7
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond	7
Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management	7
What COVID-19 can mean for people with hemophilia beyond the infection risk	7
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary	7
Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review	7
Immunodeficiency-associated Hodgkin lymphoma	7

Chronic lymphocytic leukemia prognostic models in real life: still a long way off	7
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma	7
Identification and management of fetal anemia due to hemolytic disease	7
Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review	7
Emerging pharmacotherapies for elderly acute myeloid leukemia patients	7
CD123-targeted therapy in acute myeloid leukemia	7
Copper deficiency, a rare but correctable cause of pancytopenia: a review of literature	6
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice	6
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review	6
Developments in identifying and managing mucormycosis in hematologic cancer patients	6
Complications of hemophilia in the elbow: current management	6
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances	6
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	6
The value of the red cell distribution width index versus other parameters in the differentiation between iron deficiency anemia and beta thalassemia trait among children in Mosul, Iraq	6
Palliative care for patients with hematologic malignancies: are we meeting patients’ needs early enough?	6
Chronic neutropenia: how best to assess severity and approach management?	6
Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner’s perspective	6
Resource limited centres can deliver treatment for children with acute lymphoblastic leukaemia with risk-stratified minimal residual disease based UKALL 2003 protocol with no modification and a good o	6
Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease	6
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia	6
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura	6
Hemophilic arthropathy: a teaching approach devoted to hemophilia treaters in under-development countries	6
Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents	6
Exercise and anemia in cancer patients: could it make the difference?	6
Current approaches in the treatment of catheter-related deep venous thrombosis in children	6
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma	6
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	6
Post-COVID-19 hematologic complications: a systematic review	6
Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings	5
Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma	5
Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma	5
The clinical management of factor XI deficiency in pregnant women	5
Total knee arthroplasty in hemophilia: lessons learned and projections of what’s next for hemophilic knee joint health	5
An evaluation of ferric derisomaltose as a treatment for anemia	5
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside	5
A critical evaluation of crizanlizumab for the treatment of sickle cell disease	5
Evolution of viscoelastic coagulation testing	5
Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment	5
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?	5
Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?	5
Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia	5
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors	5
How low risk are low risk myelodysplastic syndromes?	5
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid	5
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia	5
The role of platelets, neutrophils and endothelium in COVID-19 infection	5
A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma	5
Selinexor for the treatment of patients with previously treated multiple myeloma	5
Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence	4
Advances in managing rare acquired bleeding disorders	4
Voxelotor for the treatment of sickle cell disease in pediatric patients	4
Reducing infectious complications after allogeneic stem cell transplant	4
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma	4
Treatment of hairy cell leukemia	4
Risk assessment of venous thromboembolism in hematological cancer patients: a review	4
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts	4
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States	4
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review	4
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions	4
Chronic myelomonocytic leukemia - a review	4
Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines	4
Hematopoietic stem cell transplantation for classical inherited bone marrow failure syndromes: an update	4
New directions to develop therapies for people with hemophilia	4
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations	4
Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis	4
Strategies to increase access to basic sickle cell disease care in low- and middle-income countries	4
Bispecific antibodies in acute lymphoblastic leukemia therapy	4
CD43 in the malignant flow cytometry laboratory in 2020	4
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes	4
Iliopsoas hematomas in people with hemophilia: diagnosis and treatment	4
G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review	4
The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders	4
Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions	4
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients	4
Pregnancy and sickle cell disease: an overview of complications and suggested perinatal care	4
Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges	4
An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura	4
The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia	4
Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura	4
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders	4

Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease	4
Lived experience experts: a name created by us for us	4
Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia	4
Comparative study between chronic immune thrombocytopenia patients and healthy population on Epstein–Barr virus infection status by polymerase chain reaction	3
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib	3
Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review	3
Anticoagulant therapy for splanchnic vein thrombosis: recent updates for patients with liver cirrhosis	3
Smoldering multiple myeloma 40 years later: a story of unintended disease	3
D-Dimer: an analyte with increasing application in Covid-19 infection	3
Zanubrutinib for the treatment of Waldenström Macroglobulinemia	3
Emerging roles of microRNAs in acute lymphoblastic leukemia and their clinical prospects	3
An update on disease biomarkers for Hodgkin lymphoma	3
Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies	3
Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias	3
Monoclonal antibodies used for the management of hemataological disorders	3
Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy	3
Consanguineous marriage and rare bleeding disorders	3
Risk of infection in adult patients with primary immune thrombocytopenia (ITP): a systematic review	3
An evaluation of ticagrelor for the treatment of sickle cell anemia	3
The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia – are we ready for chemo-free immunotherapy approach?	3
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	3
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors	3
PTPN22 gene polymorphism as a genetic risk factor for primary immune thrombocytopenia in Egyptian children	3
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes	3
Synovitis in hemophilia: preventing, detecting, and treating joint bleeds	3
A new decade awaits sticky platelet syndrome: where are we now, how do we manage and what are the complications?	3
Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from gr	3
BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?	3
HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response	3
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin	3
Advances in viral oncolytics for treatment of multiple myeloma – a focused review	3
Trend of fluctuations of antithrombin in plasma of patients with COVID-19: a meta-analysis and systematic review	3
Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting	3
An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia	3
Pain management in people with hemophilia in childhood and young adulthood	3
Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?	3
Dysregulated MAPK signaling pathway in acute myeloid leukemia with RUNX1 mutations	3
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review	3
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management	3
Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis	3
Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach	3
What is the future of telomere length testing in telomere biology disorders?	2
Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations	2
Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia	2
Soliciting international perspectives on an American national research agenda for inherited bleeding disorders	2
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia	2
Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms	2
The current role of artificial intelligence in hemophilia	2
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A	2
Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma	2
How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies	2
Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review	2
The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis	2
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms	2
Paving the way to precision medicine in multiple myeloma	2
Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes	2
An expert spotlight on inferior vena cava filters	2
Electromagnetic radiation: a new charming actor in hematopoiesis?	2
Non-intensive acute myeloid leukemia therapies for older patients	2
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementa	2
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma	2
Emicizumab: a novel drug in hemophilia A prophylaxis – a narrative review	2
Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary	2
Recent advances in surgery and its perioperative treatment in people with hemophilia	2
Developments in consolidation and maintenance strategies in post-remission multiple myeloma	2
Osteoporosis in hemophilia: what is its importance in clinical practice?	2
The relationship between anemia and obesity	2
Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria	2
Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A	2
Advances in myelodysplastic syndromes: promising novel agents and combination strategies	2
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma	2
Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy	2
Molecular therapeutics of hemophilia A and B	2
The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia	2
Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review	2
Phenotypic variation in sickle cell disease: the role of beta globin haplotype, alpha thalassemia, and fetal hemoglobin in HbSS	2
Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies	2
Managing patients with myelofibrosis and thrombocytopenia	2
Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice	2
Testing strategies used in the diagnosis of rare inherited bleeding disorders	2
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	2
Sickle cell disease in gulf cooperation council countries: a systematic review	2
Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection	2
Factors associated with blood pressure variation in sickle cell disease patients: a systematic review and meta-analyses	2
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research to advance the health of people with inherited bleeding disorders with the pote	2
Copy-number variations in adult patients with chronic immune thrombocytopenia	2
Addressing unmet needs in rare bleeding disorders: selected poster extracts of recent research in hemophilia A and von Willebrand disease presented at the 14th Annual Congress of the European Associat	2
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis	2